PepGen reports Q3 net loss of $18.0M; 53.7% splicing correction in DM1 Phase 1

PepGen Inc.

2025-Q3 EPS reported -$2.14 vs consensus -$0.58 ▼ miss (-271.3%)

FREEDOM-DM1 15 mg/kg showed mean splicing correction of 53.7%, highest reported in DM1 patients.
All patients in FREEDOM2 5 mg/kg cohort enrolled; topline data expected Q1 2026.
Closed $115M public offering in Sept 2025; cash runway extended into H2 2027.
Net loss $18.0M ($0.52/sh) vs $21.4M ($0.66/sh) in Q3 2024; cash $163.7M at Sept 30.
R&D expense $13.4M down from $17.7M YoY; G&A flat at $5.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.